Neurobiological Markers as Predictors of Later Functional Outcome in First Episode Psychosis

项目总结 由于新冠肺炎疫情，母公司R01项目在 去年获奖，导致投资的主要组成部分(目标2)处于风险之中。另外， 首席研究员的补助金将在没有额外资金的情况下结束。因此，本补编将提供关键的 资源：i)完成拟议的纵向队列数据收集，以实现拟议的 项目目标；ii)将母公司R01项目的科学性扩展到最初的跟踪期之后，以包括 (三)为首席调查员提供急需的工资支持。 NIMH优先研究领域：检查精神疾病在整个生命周期中的轨迹。 家长项目的范围(MH109687)：确定首发精神病患者的生物类别 (FEP)使用扩展的生物标记物小组并调查生物类别作为后一种预测因素的作用 功能结果。 具体目标1：使用生物分类将FEP患者分为不同的同质亚组(Bio-Class) 基线的生物标志物和表型星座。 具体目标2a：调查基线生物类是否与以后相关并预测 两年随访期的功能结果，并收集全面的生物标记物、临床和 每个时间点的功能结果测量。 具体目标2b：检查生物分类和DSM分类之间的差异 两年内的功能结果和恢复轨迹。 所要求补充资料的贡献：虽然由于以下原因没有收集两年的跟踪数据 新冠肺炎的中断，我们预测基线生物类将继续与 预测早期疾病超过最初建议的两年后的功能结果。 因此，我们提出了一个修改后的特定目标2a：调查基线生物类是否关联 并预测疾病早期的后期功能结果。我们会把FEP病人带回来 (n=58)已经登记了基线数据并收集了随访数据的患者。后续行动 因此，这一期限将在发病后4年内延长。我们预测机器学习聚类 分析将解析出做出可靠的生物分类和预测的患者的异质性。 具体目标2b将保持不变。

PROJECT SUMMARY Due to the COVID-19 pandemic, the parent R01 project experienced significant delays and interruptions in the last year of award, resulting in substantial components (Aim 2) of the investment being at risk. Also, the principal investigator’s grants are ending with no additional funding. This supplement will thus provide a critical resource to: i) complete the proposed longitudinal cohort data collection in order to achieve the proposed project goals; ii) extend the science of parent R01 project beyond the initial follow-up period to include the early-stage illness period; iii) provide much needed salary support of the principal investigator. NIMH priority research area: Examine Mental Illness Trajectories Across the Lifespan. Scope of the Parent Project (MH109687): to characterize bio-classes of first episode of psychosis patients (FEP) using an expanded biomarker panel and to investigate the role of bio-classes as predictors of later functional outcomes. Specific Aim 1: To bio-classify FEP patients into distinct homogeneous sub-groups (bio-classes) using a constellation of biomarkers and phenotypes at baseline. Specific Aim 2a: To investigate whether baseline bio-classes are associated with and predictive of later functional outcomes over a two-year follow-up period and collect comprehensive biomarker, clinical, and functional outcome measures at each time point. Specific Aim 2b: To examine differences between bio-classes and DSM classification in associations with later functional outcomes and recovery trajectories over two-years. Contribution of the requested supplement: Although the 2-year follow-up data was not collected due to the COVID-19 disruption, we predict that baseline bio-classes will continue to be significantly associated with and predictive of later functional outcomes throughout the early-stage illness beyond the initial proposed 2 years. Therefore, we propose a Modified Specific Aim 2a: To investigate whether baseline bio-classes are associated with and predictive of later functional outcomes during early-stage illness. We will bring back FEP patients (N=58) who have already enrolled in the study with baseline data and collect follow-up data. The follow-up period will thus be extended within 4 years of illness onset. We predict that machine learning clustering analyses will parse out heterogeneity of patients making reliable bio-class classifications and predictions. Specific Aim 2b will remain unchanged.